Xeljanz tofacitinib regulatory update

Pfizer said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Xeljanz tofacitinib citrate to treat rheumatoid arthritis in adult patients who have an inadequate response to existing therapies. The pharma said Xeljanz may be used in patients in whom clinical symptoms of RA remain even after treatment with >=1 other DMARD, such as methotrexate. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan) has rights from Pfizer to co-market the oral pan-Janus kinase (JAK) inhibitor in Japan. The partners plan to launch the drug following National Health Insurance (NHI) listing. ...